Ollin Biosciences
Reviewed active Updated Jun 29, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Investors
About
Ollin Biosciences is a South San Francisco-based clinical-stage biopharmaceutical company developing therapies for vision-threatening retinal diseases 123. Its lead asset, OLN324 (also known as IBI324, an Innovent partnership program), is a VEGF/Ang2 bispecific antibody being advanced into Phase 3 trials in diabetic macular edema (DME) and wet age-related macular degeneration (AMD), with studies planned to start in the second half of 2026 123. The company has reported Phase 2 (“JADE”) data in which nearly 90% of DME patients on OLN324 achieved absence of disease at 12 weeks compared with 57% on faricimab, with numerically greater vision gains and zero intraocular inflammation 12. The Series B was raised to fund the global Phase 3 program and was oversubscribed 124.
Disclaimer: This is a lean profile built from initial round coverage and may be expanded as more information becomes available.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-06-23 | Series B | $330M | TCGX, ARCH Venture Partners (co-led) | a16z Bio+Health, Blackstone Multi-Asset Investing, Commodore Capital, Canada Pension Plan Investment Board (CPP Investments), RA Capital Management, T. Rowe Price Investment Management, Mubadala Capital, Monograph Capital, an unnamed sovereign wealth fund 1234 |
What Investors Say
No independently sourced investor quotes found at the time of this round announcement.
What Founders Say
“We are delighted to welcome a premier syndicate of new and existing investors who share our vision of advancing OLN324 as a potential new standard of care in retinal vascular disease.” — Jason Ehrlich, M.D., Ph.D., Co-Founder and CEO, Ollin Biosciences, in the Innovent partner press release, June 23, 2026 4
Sources
-
BusinessWire (Ollin Biosciences press release), “Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of OLN324 in DME and Wet AMD; Studies Commencing in Second Half of 2026,” June 23, 2026. Accessed June 2026. https://www.businesswire.com/news/home/20260623783799/en/Ollin-Biosciences-Announces-Oversubscribed-%24330-Million-Series-B-Financing-to-Advance-Global-Phase-3-Development-of-OLN324-in-DME-and-Wet-AMD-Studies-Commencing-in-Second-Half-of-202↩↩↩↩↩
-
BioSpace, “Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of OLN324 in DME and Wet AMD; Studies Commencing in Second Half of 2026,” June 23, 2026. Accessed June 2026. https://www.biospace.com/press-releases/ollin-biosciences-announces-oversubscribed-330-million-series-b-financing-to-advance-global-phase-3-development-of-oln324-in-dme-and-wet-amd-studies-commencing-in-second-half-of-202↩↩↩↩↩
-
STAT News, “Ollin Biosciences, an ophthalmology venture, grabs investors’ attention,” June 24, 2026. Accessed June 2026. https://www.statnews.com/2026/06/24/ophthalmology-biotech-ollin-biosciences/↩↩↩
-
PR Newswire (Innovent partner release), “Innovent’s Partner Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of IBI324 (OLN324) in DME and Wet AMD; Studies Commencing in Second Half of 2026,” June 23, 2026. Accessed June 2026. https://www.prnewswire.com/news-releases/innovents-partner-ollin-biosciences-announces-oversubscribed-330-million-series-b-financing-to-advance-global-phase-3-development-of-ibi324-oln324-in-dme-and-wet-amd-studies-commencing-in-second-half-of-2026-302809651.html↩↩↩